Filing Flows › AbCellera Biologics (ABCL) › R&D spending
AbCellera Biologics (ABCL) R&D spending by quarter
AbCellera Biologics' R&D spending was $46.0M in Q2 2026 (second quarter 2026), -1% from Q1 2026. Over the last 6 quarters it ranged from $39.2M (Q2 2025) to $55.0M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $46.0M | -1% | +17% |
| Q1 2026 | $46.7M | -15% | +10% |
| Q3 2025 | $55.0M | +40% | — |
| Q2 2025 | $39.2M | -8% | — |
| Q1 2025 | $42.5M | -8% | — |
| Q4 2024 | $46.1M | — | — |
Q2 2026 at a glance
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is AbCellera Biologics' R&D spending?
AbCellera Biologics' R&D spending was $46.0M in Q2 2026 (second quarter 2026), -1% from Q1 2026.
How has AbCellera Biologics' R&D spending changed?
Over the last 6 quarters it ranged from $39.2M (Q2 2025) to $55.0M (Q3 2025).